Kura Oncology Inc. (KURA)
Kura Oncology Launches $50M-Backed Diabetes Venture for Oral Menin Inhibitor
Kura Oncology NASDAQ: KURA and its newly formed affiliate Caspian Therapeutics outlined plans to develop KO-7246, an oral menin inhibitor, for diabetes, citing preclinical data that the companies said showed beta-cell expansion, improved glucose control and sustained effects after treatment ended.
Kura Oncology, Inc. (KURA) Discusses KO-7246 Data and Development Strategy for Menin Inhibitors in Diabetes Transcript
Kura Oncology, Inc. (KURA) Discusses KO-7246 Data and Development Strategy for Menin Inhibitors in Diabetes Transcript
Kura Oncology, Inc. (KURA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Kura Oncology, Inc. (KURA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
KURA Stock Gains 37.6% in a Month: Here's What You Need to Know
Kura's rising Komzifti sales, promising AML data and pipeline catalysts boost investor confidence and fuel KURA's gains.
Kura Oncology (KURA) Upgraded to Buy: What Does It Mean for the Stock?
Kura Oncology (KURA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Kura Oncology: 'Strong Buy': Ziftomenib AML Expansions With Different Regimens Could Boost KOMZIFTI's Prospects
Kura Oncology maintains a “Strong Buy” rating, driven by KOMZIFTI's FDA approval and robust early commercial performance in relapsed/refractory NPM1-mutated AML. The company achieved $9.1M net product revenue in two quarters, marking a 57% sequential increase, and targets significant market expansion via first-line AML indications. Phase 3 KOMET-017 trial topline data in 2028 and two phase 1b KOMET-007 data readouts in 2H 2026 are key catalysts for pipeline expansion and valuation.
Kura Oncology (KURA) is a Great Momentum Stock: Should You Buy?
Does Kura Oncology (KURA) have what it takes to be a top stock pick for momentum investors? Let's find out.
Does Kura Oncology (KURA) Have the Potential to Rally 178.55% as Wall Street Analysts Expect?
The mean of analysts' price targets for Kura Oncology (KURA) points to a 178.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Kura Oncology, Inc. (KURA) Q2 2026 Earnings Call Transcript
Kura Oncology, Inc. (KURA) Q2 2026 Earnings Call Transcript
Kura Oncology Q2 Earnings Call Highlights
Kura Oncology NASDAQ: KURA reported second-quarter net product revenue of $9.1 million from KOMZIFTI, its treatment for relapsed or refractory NPM1-mutated acute myeloid leukemia, as the company said the drug captured a majority share of new patient starts in the menin inhibitor market for that indication.
Kura Oncology (KURA) Reports Q2 Loss, Beats Revenue Estimates
Kura Oncology (KURA) came out with a quarterly loss of $0.77 per share versus the Zacks Consensus Estimate of a loss of $0.89. This compares to a loss of $0.75 per share a year ago.
Kura Oncology: A Menin Inhibitor Launch With More Than One Way To Win
Kura Oncology is positioning ziftomenib (KOMZIFTI) as a combination backbone in AML, not just a relapsed/refractory monotherapy. KURA's robust cash position, bolstered by Kyowa Kirin payments, is expected to fund the pivotal KOMET-017 trial through the topline readout in 2028. Recent combination data show high remission rates and tolerability, supporting the platform thesis and expanding addressable AML market potential.
